- Home
- ANIX vs ELTX Comparison
ANIX vs ELTX Comparison
Compare ANIX & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIX | ELTX |
|---|---|---|
| Founded | 1982 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 209.9M |
| IPO Year | 2013 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ANIX | ELTX |
|---|---|---|
| Price | $2.65 | $11.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $9.00 | ★ $17.00 |
| AVG Volume (30 Days) | 82.4K | ★ 139.2K |
| Earning Date | 03-09-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.82 | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | $210,000.00 | ★ $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.33 | $4.60 |
| 52 Week High | $5.46 | $14.93 |
Technical Indicators
Market Signals| Indicator | ANIX | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.58 | 48.84 |
| Support Level | N/A | $10.01 |
| Resistance Level | $3.10 | $11.12 |
| Average True Range (ATR) | 0.17 | 1.10 |
| MACD | -0.01 | -0.20 |
| Stochastic Oscillator | 6.98 | 5.10 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.